Reports that ss of December 31 Soleno had cash and cash equivalents of approximately $169.7M which includes $129M received upon the closing of the public offering and concurrent private placement in October 2023, and $43.1M received from the sale and exercise of warrants issued in connection with the December 2022 Securities Purchase Agreement. The Company may receive an additional $16.9m from the exercise of the remaining warrants issued pursuant to the December 2022 Securities Purchase Agreement….Announced positive statistically significant top-line data from the randomized withdrawal period of Study C602, a long-term treatment study of DCCR Extended-Release tablets for the treatment of Prader-Willi syndrome in September 2023.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SLNO:
- Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
- Soleno Therapeutics management to meet with Oppenheimer
- Charter downgraded, Cigna upgraded: Wall Street’s top analyst calls
- Soleno Therapeutics initiated with an Overweight at Piper Sandler
- Soleno Therapeutics Expands Equity Incentive Plan
